Opko Health Inc’s filing revealed that its CEO & Chairman FROST PHILLIP MD ET AL acquired Company’s shares for reported $0.44 million on Mar 18 ’24. In the deal valued at $0.87 per share,500,000 shares were bought. As a result of this transaction, FROST PHILLIP MD ET AL now holds 210,968,225 shares worth roughly $259.49 million.
Then, FROST PHILLIP MD ET AL bought 500,000 shares, generating $444,300 in total proceeds. Upon buying the shares at $0.89, the CEO & Chairman now owns 210,468,225 shares.
Before that, FROST PHILLIP MD ET AL bought 500,000 shares. Opko Health Inc shares valued at $463,750 were divested by the CEO & Chairman at a price of $0.93 per share. As a result of the transaction, FROST PHILLIP MD ET AL now holds 209,968,225 shares, worth roughly $258.26 million.
Barrington Research upgraded its Opko Health Inc [OPK] rating to an Outperform from a a Mkt perform in a research note published recently. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who began to cover the stock in mid December with a ‘”a Buy”‘ rating. Barrington Research also remained covering OPK and has decreased its forecast on January 24, 2022 with a “Mkt perform” recommendation from previously “an Outperform” rating. Ladenburg Thalmann started covering the stock on June 21, 2021. It rated OPK as “a Buy”.
Price Performance Review of OPK
On Friday, Opko Health Inc [NASDAQ:OPK] saw its stock fall -4.28% to $1.23. Over the last five days, the stock has lost -8.89%. Opko Health Inc shares have fallen nearly -18.54% since the year began. Nevertheless, the stocks have fallen -16.33% over the past one year. While a 52-week high of $2.24 was reached on 01/02/24, a 52-week low of $0.85 was recorded on 01/05/24. SMA at 50 days reached $1.0511, while 200 days put it at $1.4300. A total of 4.74 million shares were traded, compared to the trading of 3.36 million shares in the previous session.
Levels Of Support And Resistance For OPK Stock
The 24-hour chart illustrates a support level at 1.2035, which if violated will result in even more drops to 1.1771. On the upside, there is a resistance level at 1.2629. A further resistance level may holdings at 1.2959. The Relative Strength Index (RSI) on the 14-day chart is 56.79, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.0063, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 38.83%. Stochastics %K at 67.79% indicates the stock is a holding.
The most recent change occurred on November 25, 2019 when Piper Jaffray began covering the stock and recommended ‘”an Overweight”‘ rating along with a $2.50 price target.
